Okogen Inc. Submits Regulatory Application for Phase IIb Clinical Trial in India
Okogen Inc. announces regulatory submission for Phase IIb clinical trial, appoints Dr. Hollander as CMO. The Emerald Study aims to evaluate triple-combination eyedrop for bacterial and viral conjunctivitis.
This news matters as Okogen's innovative approach to treating acute infectious conjunctivitis could potentially revolutionize the ophthalmology field. The appointment of Dr. Hollander and the upcoming clinical trial signify a significant step towards addressing the unmet needs of patients suffering from this condition.